Manatuck Hill Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Manatuck Hill Partners’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-317,322	Closed	-$747K	–	102
2018 Q1	$747K	Sell	317,322 -84,811	-21%	-$199K	0.4%	54
2017 Q4	$756K	Hold	402,133	–	–	0.39%	53
2017 Q3	$999K	Sell	402,133 -306,927	-43%	-$761K	0.49%	43
2017 Q2	$1.95M	Hold	709,060	–	–	0.98%	31
2017 Q1	$2.14M	Sell	709,060 -125,730	-15%	-$357K	0.93%	36
2016 Q4	$2.64M	Sell	834,790 -171,450	-17%	-$526K	1.29%	25
2016 Q3	$3.43M	Hold	1,006,240	–	–	1.37%	27
2016 Q2	$2.3M	Sell	1,006,240 -107,785	-10%	-$264K	1.01%	29
2016 Q1	$2.8M	Sell	1,114,025 -313,750	-22%	-$700K	0.99%	29
2015 Q4	$4.72M	Hold	1,427,775	–	–	1.58%	21
2015 Q3	$3.46M	Hold	1,427,775	–	–	1.47%	23
2015 Q2	$4.18M	Sell	1,427,775 -160,700	-10%	-$623K	1.28%	25
2015 Q1	$6.37M	Hold	1,588,475	–	–	1.72%	17
2014 Q4	$4.78M	Buy	+1,588,475	New	+$4.3M	1.04%	30

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Manatuck Hill Partners's LCTX Position: Q2 2018 in Review

Manatuck Hill Partners sold out of Lineage Cell Therapeutics (LCTX) in Q2 2018, closing a stake of 317,322 shares — an estimated $747K sold.

Manatuck Hill Partners first reported a position in LCTX in Q4 2014 and held it in 14 quarters. The position peaked at $6.37M in Q1 2015. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2018.

Manatuck Hill Partners reported no remaining Lineage Cell Therapeutics position as of Q2 2018 after selling out during the quarter.
Manatuck Hill Partners sold 317,322 Lineage Cell Therapeutics shares in Q2 2018, an estimated $747K.
Manatuck Hill Partners first reported a position in Lineage Cell Therapeutics in Q4 2014 and held it in 14 quarters.
Manatuck Hill Partners's Lineage Cell Therapeutics position peaked at $6.37M in Q1 2015.
107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2018.

Based on Manatuck Hill Partners's 13F filing for Q2 2018, filed 14 Aug 2018.